

CORRECTIONS

Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials

In the final stages of production, the authors of this paper, Bianca Hemmingsen and colleagues, made some late changes to data in the 14 figures, resulting in some errors in the published article (*BMJ* 2011;343:d6898, doi:10.1136/bmj.d6898). Additionally, after publication they also noticed some further errors. In the abstract and results section, the P value for retinopathy should be 0.008 [rather than 0.009] and the number of participants should be 10 070 [not 10 793]. The trial sequential analysis adjusted 95% confidence interval for retinopathy should be 0.55 to 1.15 [not 0.54 to 1.17]. Figure 10↓ and figure 11↓ have been corrected; and in the legend to fig 11, the heterogeneity adjusted required information size is 40 021 [not 43 960] participants calculated on the basis of

proportion of retinopathy of 15.5% [not 14.3%] in the conventional glucose control group, and the number of participants is as above. In table 2, the conventional glycaemic control column for Jaber et al 1996 and REMBO 2008 should read “Standard treatment” [rather than “Not specified”]. Table 4↓ contained incorrect information for selective outcome reporting bias and had been corrected. Finally, in appendix 3 of the webextra (original re-posted here), the retinopathy outcome for UGDP 1975 should be “Fundus abnormalities excluding exudates.”

Cite this as: *BMJ* 2012;344:d8277

© BMJ Publishing Group Ltd 2012

Table


Table 4 (Corrected) | Risk of bias assessments of included trials

Trial	Sequence generation	Allocation concealment	Blinding	Incomplete outcome data	Selective outcome reporting	Free from other bias
ACCORD 2008 ^{4 67-74}	Adequate	Adequate	Adequate	Unclear	Adequate	Inadequate
ADVANCE 2008 ⁷⁵⁻⁷⁸	Adequate	Adequate	Adequate	Adequate	Adequate	Inadequate
Bagg et al 2001 ⁷⁹⁻⁸²	Unclear	Unclear	Adequate	Adequate	Adequate	Adequate
Becker et al 2003 ^{83 84}	Unclear	Unclear	Unclear	Unclear	Unclear	Adequate
IDA 2009 ^{92 93}	Adequate	Adequate	Adequate	Adequate	Unclear	Inadequate
Jaber et al 1996 ⁹⁴	Unclear	Unclear	Unclear	Adequate	Unclear	Inadequate
Kumamoto 2000 ^{7 95 96}	Unclear	Unclear	Unclear	Adequate	Unclear	Inadequate
Lu et al 2010 ⁹⁶	Unclear	Unclear	Unclear	Unclear	Unclear	Adequate
REMBO 2008 ⁸⁵	Unclear	Unclear	Unclear	Adequate	Unclear	Unclear
Service et al 1983 ⁸⁷	Adequate	Unclear	Adequate	Adequate	Unclear	Adequate
UGDP 1978 ⁸⁸⁻⁹¹	Adequate	Adequate	Adequate	Adequate	Adequate	Adequate
UKPDS 1998 ^{1 8 97-102}	Adequate	Adequate	Adequate	Adequate	Adequate	Inadequate
VA CSDM 1995 ¹⁰³⁻¹⁰⁹	Unclear	Unclear	Adequate	Adequate	Adequate	Inadequate
VADT 2009 ^{6 110 111}	Adequate	Adequate	Adequate	Adequate	Adequate	Inadequate

ACCORD=Action to Control Cardiovascular Risk in Diabetes Study; ADVANCE=Action in Diabetes and Vascular disease—PreterAx and DiamicroN MR Controlled Evaluation; IDA=Insulin Diabetes Angioplasty; REMBO=Rational Effective Multicomponent Therapy in the Struggle Against Diabetes Mellitus in Patients With Congestive Heart Failure; UGDP=University Group Diabetes Program; UKPDS=United Kingdom Prospective Diabetes Study; VACSDM=Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus; VADT=Veterans Affairs Diabetes Trial.

Figures

Corrected Figure 10



Corrected Figure 11

